US Equities Analysis

WST — West Pharmaceutical Services

WST Price Chart FCF Yield Dividend Yield Price / Earnings Price / Book EV / EBITDA EV / NOPAT Consensus EPS Broker Sentiment EBITDA Margin EBIT Margin ROIC & ROE Capital Turnover Capex & WC / Sales Net Debt / Equity Price and 100d MA Relative to Index Relative to MSCI


1. Industry Fundamentals

1.1 Cyclicality

The company operates in a cyclical industry sensitive to macroeconomic conditions. Revenue and earnings tend to correlate with broader economic cycles, with periods of expansion driving growth and contractions creating headwinds. Current market capitalisation: 23.38B.

1.2 Competition

The industry is moderately competitive with established players and meaningful barriers to entry. Beta of 1.18 suggests moderate market sensitivity. Competitive advantages stem from brand, scale, or regulatory moats.

1.3 Technology

Key technology drivers include digital transformation, operational efficiency, automation. Companies that invest in R&D and adopt new technologies tend to gain market share. The pace of technological change creates both opportunities for innovation and risks of disruption.


2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 21.7%
Profit Margins 16.85%
Return on Equity 19.13%
Return on Assets 11.21%
Free Float 0.07B
Dividend Yield 0.25%
Short Int % Utilisation 3.84%

2.2 Growth

Metric Value
Revenue Growth 21.0%
Free Cash Flow 0.28B
EBITDA 26.64 (Ratio)
Enterprise Value 23.18B
EV/Revenue 7.2
EV/EBITDA 26.64

Revenue growth of 21.0% places the company in a high-growth category.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.) 8.12%
Risk / Std Dev (Ann.) 40.62%
Sharpe Ratio (rf=4.5%) 0.09
Beta 1.18

2.5 Valuation

Metric Value
P/E (Forward) 34.63
Price/Book 7.98
EV/Revenue 7.2
EV/EBITDA 26.64
Enterprise Value / NOPAT 34.29
FCF Yield (%) 1.16%
Price / Earnings 45.03
Price / Book 7.98
Enterprise Value / EBITDA 27.09

Forward P/E of 35x is at a moderate premium, reflecting growth expectations.

2.6 Return Outlook

The stock’s historical risk-return profile shows an annualised expected return of 8.1% with annualised volatility of 40.6%, yielding a Sharpe ratio of 0.09 (rf=4.5%). The risk-adjusted return is positive but modest on a historical basis. With a beta of 1.2, the stock moves broadly in line with the market.


us-equitystockequitywsthealth-carehealth-care-suppliesnasdaq